Bosutinib 100 mg, 400 mg, 500 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 100 mg, 400 mg, 500 mg

Reference Brands: Bosulif (USA)

Category: Oncology Cancer Care

Bosutinib is an oral tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML). It works by blocking the BCR-ABL kinase enzyme that promotes the growth of cancerous white blood cells. Marketed under the brand name Bosulif, it is available as film-coated tablets in 100 mg, 400 mg, and 500 mg strengths. It is indicated for patients who are newly diagnosed or resistant/intolerant to prior TKI therapy.

Product Description:

Bosutinib is a dual SRC and ABL kinase inhibitor. In chronic myeloid leukaemia the BCR-ABL fusion protein drives uncontrolled myeloid proliferation, and bosutinib inhibits it, including many of the mutations that cause resistance to imatinib — with the notable exception of T315I, the gatekeeper mutation, against which it is inactive. It inhibits the platelet-derived growth factor and KIT receptors much less than imatinib does, which shifts its side effect profile.

It is used for chronic myeloid leukaemia, first-line and after failure or intolerance of prior tyrosine kinase inhibitors. Its distinguishing adverse effect is gastrointestinal: diarrhoea affects a large majority of patients, usually early, usually manageable, but it is the reason many stop. Liver enzyme elevations are common and monitored, and fluid retention and rash occur. Compared with other agents in the class it has less cardiovascular and pleural toxicity, which matters for older patients treated for years.

Sourcing notes. Patent position varies by market. CML treatment is lifelong for most patients, so per-patient volume is high and adherence decides outcomes. BCR-ABL mutation testing guides drug selection after failure and should be available locally.